Literature DB >> 20972990

Free-solution interaction assay of carbonic anhydrase to its inhibitors using back-scattering interferometry.

Ereny F Morcos1, Amanda Kussrow, Carolyn Enders, Darryl Bornhop.   

Abstract

Back-scattering interferometry (BSI) is a label-free, free-solution, small-volume technique used for characterizing binding interactions, which is also relevant to a growing number of biosensing applications including drug discovery. Here, we use BSI to characterize the interaction of carbonic anhydrase enzyme II with five well-known carbonic anhydrase enzyme II inhibitors (± sulpiride, sulfanilamide, benzene sulfonamide, dansylamide, and acetazolamide) in the presence of DMSO. Dissociation constants calculated for each interaction were consistent with literature values previously obtained using surface plasmon resonance and fluorescence-based competition assays. Results demonstrate the potential of BSI as a drug-screening tool which is fully compatible with DMSO and does not require immobilization or labeling, therefore allowing binding interactions to be characterized in the native state. BSI has the potential for reducing labor costs, sample consumption, and assay time while providing enhanced reliability over existing techniques.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20972990      PMCID: PMC3997304          DOI: 10.1002/elps.201000389

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  16 in total

1.  Analytical characterization of chiral drug-protein interactions: comparison between the optical biosensor (surface plasmon resonance) assay and the HPLC perturbation method.

Authors:  Robert Arnell; Natalia Ferraz; Torgny Fornstedt
Journal:  Anal Chem       Date:  2006-03-01       Impact factor: 6.986

Review 2.  Optical biosensors: where next and how soon?

Authors:  Matthew A Cooper
Journal:  Drug Discov Today       Date:  2006-10-19       Impact factor: 7.851

3.  Comparative analysis of 10 small molecules binding to carbonic anhydrase II by different investigators using Biacore technology.

Authors:  Giuseppe A Papalia; Stephanie Leavitt; Maggie A Bynum; Phinikoula S Katsamba; Rosemarie Wilton; Huawei Qiu; Mieke Steukers; Siming Wang; Lakshman Bindu; Sanjay Phogat; Anthony M Giannetti; Thomas E Ryan; Victoria A Pudlak; Katarzyna Matusiewicz; Klaus M Michelson; Agnes Nowakowski; Anh Pham-Baginski; Jonathan Brooks; Bryan C Tieman; Barry D Bruce; Michael Vaughn; Michael Baksh; Yun Hee Cho; Mieke De Wit; Alexandra Smets; Johan Vandersmissen; Lieve Michiels; David G Myszka
Journal:  Anal Biochem       Date:  2006-09-07       Impact factor: 3.365

4.  Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides.

Authors:  Alessandro Cecchi; Scott D Taylor; Yong Liu; Bryan Hill; Daniela Vullo; Andrea Scozzafava; Claudiu T Supuran
Journal:  Bioorg Med Chem Lett       Date:  2005-10-03       Impact factor: 2.823

5.  The potential role of fecal carbonic anhydrase II in screening for colorectal cancer.

Authors:  S Yokoyama; C H Shatney; H Mochizuki; K Hase; D L Johnson; S Cummings; M L Trollope; S Tamakuma
Journal:  Am Surg       Date:  1997-03       Impact factor: 0.688

Review 6.  Survey of the year 2008: applications of isothermal titration calorimetry.

Authors:  Robert J Falconer; Anita Penkova; Ilian Jelesarov; Brett M Collins
Journal:  J Mol Recognit       Date:  2010 Sep-Oct       Impact factor: 2.137

Review 7.  Use of surface plasmon resonance to probe the equilibrium and dynamic aspects of interactions between biological macromolecules.

Authors:  P Schuck
Journal:  Annu Rev Biophys Biomol Struct       Date:  1997

8.  Carbonic anhydrase isoenzymes in the rat kidney. Effects of chronic acetazolamide treatment.

Authors:  G Lönnerholm; P J Wistrand; E Bárány
Journal:  Acta Physiol Scand       Date:  1986-01

9.  Catalysis and inhibition of human carbonic anhydrase IV.

Authors:  T T Baird; A Waheed; T Okuyama; W S Sly; C A Fierke
Journal:  Biochemistry       Date:  1997-03-04       Impact factor: 3.162

Review 10.  Acetazolamide: future perspective in topical glaucoma therapeutics.

Authors:  Indu Pal Kaur; R Smitha; Deepika Aggarwal; Mona Kapil
Journal:  Int J Pharm       Date:  2002-11-06       Impact factor: 5.875

View more
  6 in total

1.  Histone demethylase LSD1 is a folate-binding protein.

Authors:  Zigmund Luka; Frank Moss; Lioudmila V Loukachevitch; Darryl J Bornhop; Conrad Wagner
Journal:  Biochemistry       Date:  2011-05-05       Impact factor: 3.162

Review 2.  Interferometric methods for label-free molecular interaction studies.

Authors:  Amanda Kussrow; Carolyn S Enders; Darryl J Bornhop
Journal:  Anal Chem       Date:  2011-11-07       Impact factor: 6.986

3.  Quantitative Characterization of Three Carbonic Anhydrase Inhibitors by LESA Mass Spectrometry.

Authors:  Eva Illes-Toth; Christopher J Stubbs; Emma K Sisley; Jeddidiah Bellamy-Carter; Anna L Simmonds; Todd H Mize; Iain B Styles; Richard J A Goodwin; Helen J Cooper
Journal:  J Am Soc Mass Spectrom       Date:  2022-06-08       Impact factor: 3.262

4.  Back-scattering interferometry: an ultrasensitive method for the unperturbed detection of acetylcholinesterase-inhibitor interactions.

Authors:  Gabrielle L Haddad; Sherri C Young; Ned D Heindel; Darryl J Bornhop; Robert A Flowers
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-04       Impact factor: 15.336

5.  Therapeutic Delivery of H2S via COS: Small Molecule and Polymeric Donors with Benign Byproducts.

Authors:  Chadwick R Powell; Jeffrey C Foster; Benjamin Okyere; Michelle H Theus; John B Matson
Journal:  J Am Chem Soc       Date:  2016-10-07       Impact factor: 15.419

6.  Membrane Association Dictates Ligand Specificity for the Innate Immune Receptor NOD2.

Authors:  Amy K Schaefer; James E Melnyk; Michael M Baksh; Klare M Lazor; M G Finn; Catherine Leimkuhler Grimes
Journal:  ACS Chem Biol       Date:  2017-07-25       Impact factor: 5.100

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.